SEARCH

SEARCH BY CITATION

References

  • Alexanian, R., Weber, D., Giralt, S., Dimopoulos, M., Delasalle, K., Smith, T. & Champlin, R. (2001) Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant, 27, 10371043.
  • Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 9197.
  • Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Monconduit, M., Hulin, C., Caillot, D. & Bouabdallah, R. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 349, 24952502.
  • Barlogie, B., Smallwood, L., Smith, T. & Alexanian, R. (1989) High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Annals of Internal Medicine, 110, 521525.
  • Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, M., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B. & Crowley, J. (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93, 5565.
  • Barlogie, B., Tricot, G., Rasmussen, E., Anaissie, E., Van Rhee, F., Zangari, M., Fassas, A., Hollmig, K., Pineda-Roman, M., Shaughnessy, J., Epstein, J. & Crowley, J. (2005) Total therapy 2 without thalidomide: comparison with total therapy 1: role of intensified induction and post-transplant consolidation therapies. Blood, 107, 26332638.
  • Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., Van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krisha, S., Fox, M. & Crowley, J. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. New England Journal of Medicine, 354, 10211030.
  • Bataille, R. & Harousseau, J.L. (1997) Multiple myeloma. New England Journal of Medicine, 336, 16571664.
  • Blade, J., Samson, D., Reece, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating response in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. British Journal of Haematology, 102, 11151123.
  • Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T., Selby, P.J. & Medical Research Council Adult Leukaemia Working Party. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine, 348, 18571883.
  • Cox, D.R. (1972) Regression tables and life tables. Journal of Royal Statistical Society B, 34, 187202.
  • Dhodapkar, M., Zhan, F., Rasmussen, E., Burington, B., Durie, B., Crowley, J. Barlogie, B. & Shaughnessy, J. (2005) Gene expression profiling of bulk CD138+ plasma cells in pre-neoplastic gammopathy/asymptomatic myeloma identifies distinct subsets of patients. Blood, 106, 1218, 355a.
  • Dimopoulos, M.A., Barlogie, B., Smith, T.L. & Alexanian, R. (1991) High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Annals of Internal Medicine, 115, 931935.
  • Dimopoulos, M.A., Moulopoulos, L.A., Maniatis, A. & Alexanian, R. (2000) Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood, 96, 20372044.
  • Durie, B.G., Jacobson, J., Barlogie, B. & Crowley, J. (2004) Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials. Journal of Clinical Oncology, 22, 18571863.
  • Gooley, T.A., Leisering, W., Crowley, J. & Storer, B.E. (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistical Medicine, 18, 695706.
  • International Myeloma Working Group. (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology, 121, 749757.
  • Jagannath, S., Durie, B.G., Wolf, J., Camacho, E., Irwin, D., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schennkein, D. & Crowley, J. (2005) Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated symptomatic multiple myeloma. British Journal of Haematology, 129, 776783.
  • Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457481.
  • Kyle, A., Therneau, T.M., Rajkumar, S.V., Remstein, E.D., Offord, J.R., Larson, D.R., Plevak, M.F. & Melton, L.J., Jr. (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346, 564569.
  • Orlowski, R., Voorhees, P., Garcia, R.A., Hall, M.D., Kudrik, F.J., Allred, T., Johri, A.R., Jones, P.E., Ivanova, A., Van Deventer, H.W., Gabriel, D.A., Shea, T.C., Mitchell, B.S., Adams, J., Esseltine, D.L., Trehu, E.G., Green, M., Lehman, M.J., Natoli, S., Collins, J.M., Lindley, C.M. & Dees, E.C. (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 105, 30583065.
  • Palumbo, A., Falco, P. & Musto, P. (2005a) Oral Revlimid plus melphalan and prednisone for newly diagnosed multiple myeloma. Blood, 106, 231a.
  • Palumbo, A., Ambrosini, M.T. & Pregno, P. (2005b) VelcadeTM plus melphalan, prednisone and thalidomide (V-MPT) for advanced multiple myeloma. Blood, 106, 717a.
  • Rajkumar, S.V. & Greipp, P.R. (1999) Prognostic factors in multiple myeloma. Hematology Oncology Clinics of North America, 13, 12951314.
  • Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., Dispenzieri, A., Geyer, S.M., Kabat, B., Zeldenrust, S.R., Kumar, S., Greipp, P.R., Fonseca, R., Lust, J.A., Russell, S.J., Kyle, R.A., Witzig, T.E. & Gertz, M.A. (2005) Combination therapy with lenalidomide plus dexamethasone (REV/DEX) for newly diagnosed myeloma. Blood, 106, 40504053.
  • Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. & Anderson, K.C. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 30633067.
  • Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, J., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 26092617.
  • Shipp, M.A. (1994) Prognostic factors in aggressive non-Hodgkin's lymphoma: who has ‘‘high-risk’’ disease? Blood, 83, 1165.
  • Tricot, G., Carrabba, M., Barlogie, B., Epstein, J., Shaughnessy, J. & Corradini, P. (2004) High frequency of molecular remissions (m-CR) in multiple myeloma patients achieving a hematologic complete remission (CR) on total therapy 2 (TT-2). Blood, 104, 267a.
  • Wang, M., Delasalle, K. & Giralt, S. (2005) Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood, 106, 231a.
  • Weber, D.M., Dimopoulos, M., Moulopoulos, L.A., Delasalle, K.B., Smith, T. & Alexanian, R. (1997) Prognostic features of asymptomatic multiple myeloma. British Journal of Haematology, 97, 810814.
  • Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., Van Rhee, F., Fassas, A., Crowley, J., Tricot, G., Barlogie, B. & Shaughnessy, J., Jr. (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood, 99, 17451757.
  • Zhan, F., Huang, Y., Colla, S., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Holmig, K., Zangarri, M., Pineada-Roman, M., Van Rhee, F., Burington, B., John Crowley, J., Tricot, G., Barlogie, B. & Shaughnessy, J. Jr (2006) The molecular classification of multiple myeloma. Blood, 108, 20202028.